ROSEN, ADVISOR TO LEADING INVESTORS, Encourages BioMarin Pharmaceutical Inc. Investors With Losses Over $ 100,000 To Obtain Legal Advice Before Important Dec. 22 Deadline in Securities Class Action – BMRN | national news


NEW YORK, December 14, 2021 / PRNewswire / –

WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Recourse Period”), 22 December 2021 lead applicant time limit.

SO WHAT: If you purchased BioMarin securities during the Class Period, you may be entitled to compensation without payment of any costs or reimbursable charges through a contingency fee agreement.

WHAT TO DO NEXT: To join the BioMarin class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing or for information on the class action. A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court not later than 22 December 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing opinions do not have significant experience, resources or recognition by their peers. Many of these companies do not actually litigate class actions in securities. Be wise in choosing a lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company achieved more than $ 438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as Titan of the Plaintiff’s Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) BMN 307, an AAV5-mediated gene therapy, was less safe than BioMarin had led investors to believe; (2) The safety profile of BMN 307 made it likely that the United States Food and Drug Administration (FDA) would put a clinical suspension on the Phearless Phase 1/2 study; (3) as a result, BioMarin overestimated the clinical and commercial prospects of BMN 307; and (4) accordingly, the defendants’ public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.

To join the BioMarin class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing or for information on the class action.

No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future payback does not depend on whether he is a principal applicant.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook:

Lawyer advertising. Previous results do not guarantee a similar result.

Contact details:

Laurence Rosen, Esq.

Phillip Kim, Esq.

Rosen Law Firm, Pennsylvania

275 Madison Avenue, 40th Floor

New York, New York State 10016

Phone. : (212) 686-1060

Toll free: (866) 767-3653

Fax: (212) 202-3827

View original content to download multimedia: advice-before-important-December-22-deadline-in-the-classic-recourse-in-titles – bmrn-301444750.html

SOURCE Rosen Law Firm, PA


Comments are closed.